[ET Net News Agency, 4 July 2018] Sino Biopharmaceutical (01177) said Iodixanol
Injection, a generic drug developed by its subsidiary Nanjing Chia Tai Tianqing
Pharmaceutical Co., Ltd, has obtained approval for drug registration by the National Drug
Administration of the People's Republic of China.
Such approval is a breakthrough of the Group in the X-ray diagnostic field.
Iodixanol is the only X-ray diagnostic contrast agent that is isotonic with blood, and
has the advantages of high cardiac safety, strong kidney tolerance, more comfortable to
patients and less interference with cardiopulmonary circulation. Iodixanol is recognized
and recommended by numerous domestic and overseas clinical guidelines and expert consensus
for enhancing lesion detection rate and functioning as diagnostic identification in the
examinations of organ diseases in the nervous and cardiovascular systems, chest, abdomen,
pelvis, etc. (HL)